Johnson & Johnson (J&J) has agreed to acquire Ollin Biosciences for USD 2.2 billion upfront plus up to USD 1.125 billion in regulatory and commercial milestones, and will separately secure USD 750 million in development funding from Blackstone tied to the Phase III programme for OLN324, with Blackstone eligible for milestone payments and single-digit royalties.
OLN324 originates from Innovent Biologics and is a bispecific antibody (BsAb) against VEGF-A and Ang2 for retinal diseases, designed to modulate both angiogenic pathways in a single molecule.
Early data suggest a clear edge over Roche's faricimab. In diabetic macular oedema, OLN324 improved retinal drying by 75% more at week 1 and 50% more at week 12, with nearly 90% of patients reaching fluid resolution versus 57% for faricimab, while in wet age-related macular degeneration visual gains appeared within one week and exceeded comparator effects by week 12.

Email us at pmc@pharmcube.com for a free database trial, exclusive reports, or a 1-on-1 consultation